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ABSTRACT
Using sclareol and sclareolide as starting materials, the guanidine
derivatives of 12-amino-11-dihomodrimane-8a-ol and 13-amino-
14,15-bis-dinorlabd-8(9)-ene were synthesized by the reaction
of the corresponding amines with sodium hydrogencyanamide
in ethanol – water solution. Monoacyl- and diacylguanidines
were prepared from activated with N,N-carbonyldiimidazole
D8,9-bicyclohomofarnesenoic acid by the reaction with guanidine.
Their structures were confirmed by the 1H and 13C NMR, IR spec-
tral and elemental analysis data. The compounds 12, 13 and 15
were screened for their antiproliferative and cytotoxicity activities
against Colo 205, Colo 320 and MRC 5 human lung fibroblasts
with respect to standard drug, Cisplatin. The compounds 12 and
15 exhibits excellent results than positive control. Hence these
two compounds may be act as drug lead molecules in cancer
chemotherapy.
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1. Introduction
Numerous natural and synthetic guanidines, including terpenoid guanidines, exhibit a
broad spectrum of biological activity such as anti-inflammatory, antiprotozoal, anti-HIV,
antitumor, antidiabetic, antifungal, and antimicrobial (Zarraga et al. 2008; Mo et al.
2009; Berlinck and Romminger 2016; Carbone et al. 2017). Recently (Zarraga et al.
2008) the preparation of 11-guanidinodrimene 1 from drimenol was reported. This
compound possess antifungal activity against Candida albicans (MIC 32 mg/mL). In
addition, other researchers (Das et al. 2009) described the synthesis of the guanidino-
retinoid 3 from the all-trans retinoic acid 2, using N,N-carbonyldiimidazole (CDI) as a
carboxylic acid activating agent, while E,E-farnesoyl-guanidine 4, actinofide 5, and a
series of its analogues were synthesized for biological screening. Among all tested
compounds, the synthetic derivative N,N-difarnesoylguanidine 6 showed marked anti-
cancer activity (Carbone et al. 2017) (Figure 1).
In a search for new biologically active compounds, we synthesized previously a
number of different nitrogen-containing drimane, homodrimane, and dihomodrimane
derivatives: amines (Kuchkova et al. 2014), amides and acid hydrazides (Kuchkova
et al. 2014, 2015; Aricu et al. 2016), sesquiterpenoids with azine, hydrazide, and dihy-
drazide fragments (Aricu et al. 2016). In continuation of our investigation in this field,
we report on the synthesis of new dihomodrimane and 14,15-bis-norlab-
dane guanidines.
2. Results and discussion
2.1. Chemistry
Guanidine-containing compounds can be straightforwardly synthesized starting from
the amines (Zarraga et al. 2008) or from the acids (Das et al. 2009; Carbone et al.
2017). In this article, we describe the preparation of guanidine derivatives of 12-
amino-11-dihomodrimane-8a-ol (8), 13-amino-14,15-bis-norlabd-8(9)-ene (11), and also
D8,9-bicyclohomofarnesenoic acid (14). Amine 8 was synthesized from sclareolide 7 as
described previously by us (Kuchkova et al. 2014). The synthesis of amine 11 was also
reported recently (Kuchkova et al. 2014). The reaction of amines 8 and 11 with sodium
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Figure 1. The synthesized terpene guanidines.
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hydrogencyanamide in ethanol – water (5:1) solution gave guanidine derivatives 9, 12
and 13 (Scheme 1). (Experimental part, see Supplementary Materials).
The starting material for the guanidines 15 and 16 synthesis was D8,9-bicyclohomo-
farnesenoic acid 14, which was prepared from sclareolide 7 (six steps, 62%
overall yield), as described in our article (Aricu et al. 2016). The acid 14 was activated
with CDI in DMF, then treated with a solution of guanidine in DMF at room
temperature and generated N-(D8,9-bicyclohomofarnesenoyl)-guanidine (15) and
N,N0-di(D8,9-bicyclohomofarnesenoyl)-guanidine (16) (Scheme 2). (Experimental part,
see Supplementary Materials).
The data of elemental analysis and the1H and 13C NMR, IR spectral data of
compounds 9, 12, 13, 15, 16 confirm their structure. (See Supplementary Materials).
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Scheme 2. Reaction pathway for the preparation of D8,9-bicyclohomofarnesenoic acid guanidine
derivatives.
(a) CDI, 20 C, 1 h, then addition to a guanidine solution in DMF – dioxane (1:1), obtained from guanidine HCl and
t-BuOK, and the stirring, 20 C, 28 h, under Ar.
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Scheme 1. Reaction pathway for the preparation of guanidine derivatives of amines.
(a) NH(Na)CN, AcOH; EtOH – H2O (5:1), 20 C, 48 h; (b) NH(Na)CN, AcOH; EtOH – H2O (5:1), 20 C, 24 h, D, 20 h.
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In the 1H NMR of compound 9, chemical shifts of 6.76 (1H, br. s, C = NH) ppm, 5.43
(3H, br. s, NH and NH2) ppm and 160.1 (C = NH) ppm in
13C NMR spectrum show the
existence of guanidine fragment in this compound. Similarly, the presence of chemical
shifts of 6.25–5.13 (8H, m, 2  (2NH and NH2) ppm in 1H NMR spectrum and 167.1 (C
= NH) ppm in 13C NMR spectrum confirm the structure of compound 12 as the mix-
ture of diastereoisomers. Chemical shifts of 5.59 (1H, br. s, C = NH) ppm, 5.39 (2H, br.
s, 2NH) ppm in 1H NMR spectrum and 169.3 (C = NH) ppm in 13C NMR show that
compound 13 has the structure of the disubstituted guanidine. The presence of chem-
ical shifts of 7.05 (4H, br. s, 2NH and NH2) ppm in
1H NMR spectrum and 184.1 (C = O)
ppm, 162.5 (C = NH) ppm in 13C NMR spectrum of compound 15 and also chemical
shifts of 7.70 (1H, s, C = NH) ppm, 7.11 (2H, s, 2 NH) ppm in 1H NMR spectrum and
176.4 (2  (CO)) ppm, 157.4 (C = NH) ppm in 13C NMR of compound 16 confirm
their structures.
2.2. In vitro evaluation of the antiproliferative and cytotoxic activity
The biological evaluation of the compounds was carried out using antiproliferative
and cytotoxicity assays in doxorubicin-sensitive Colo 205 and doxorubicin resistant
Colo 320 human colonic adenocarcinoma cell lines, suggesting that they have
potential to be drug candidates for cancer treatment.
In order to determine the activity of compounds on cell proliferation, a low cell
number (6  103 cells/well) was chosen and the incubation period of the MTT assay
was 72 h. Cisplatin was used as a positive control. Compounds 12 and 15 exerted
potent antiproliferative activity on both colon adenocarcinoma cell lines (IC50 between
3.36 and 7.86 mM). Compound 13 had more pronounced activity on the sensitive cell
line compared to the ABCB1 transporter expressing resistant cell line (IC50 10.64 and
37.02, respectively) (Table 1).
In the cytotoxicity assay, a high cell number (2  104 cells/well) was used and
the inhibition of cell growth was determined after 24 h by MTT assay in order to
investigate the toxicity of the compounds. Cisplatin was used as a positive control and
cytotoxicity was measured in normal human embryonal lung fibroblast cells (MRC-5)
as well. The solvent DMSO did not affect the viability of the cells. Compounds 12 and
15 possessed strong cytotoxic activity on the sensitive and resistant colon adenocar-
cinoma cell lines (IC50 between 4.12 and 7.02 mM), while compound 13 was less active
on these tumor cell lines (IC50 between 24 and 32 mM) (Table 1). Interestingly, com-
pounds 12, 13 and 15 had lower cytotoxic activity on normal lung fibroblast cells
implicating the selective toxicity of the compounds. Comparing the cytotoxic activity
Table 1. Antiproliferative and cytotoxic effect of compounds on normal MRC5 fibroblasts and
colon adenocarcinoma cells.
Compound
Antiproliferative effect (lM) Cytotoxic effect (lM)
Colo 205
sensitive
Colo 320
resistant
Colo 205
sensitive
Colo 320
resistant
MRC5 human
lung fibroblasts
12 3.36 ± 0.69 3.45 ± 1.10 4.12 ± 1.18 7.02 ± 1.92 15.34 ± 4.8
13 10.64 ± 2.64 37.02 ± 5.67 31.57 ± 5.13 24.52 ± 6.85 44.18 ± 8.1
15 7.86 ± 2.41 4.21 ± 1.15 5.61 ± 1.40 5.09 ± 1.21 20.28 ± 7.42
Cisplatin 23.2 ± 2.95 9.74 ± 3.11 66.77 ± 4.62 12.17 ± 1.01 44.12 ± 1.28
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of the compounds to cisplatin, the compounds showed more potent cytotoxic activity
with selectivity towards tumor cells.
3. Conclusions
The new dihomodrimane and 14,15-bis-norlabdane guanidines were synthesized from
commercially available sclareolide and sclareol. The assessment of anticancer activity
of these compounds showed that two of the tested guanidines display more potent
antiproliferative and cytotoxic activity than cisplatin against Colo 205 and Colo 320
cell lines and may be act drug lead molecules in cancer chemotherapy.
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